尼美舒利治疗男性慢性盆腔疼痛综合征临床试验

Observation of Curative Effects of Nimesulide on Male Chronic Pelvic Pain Syndrome

目的:评价尼美舒利治疗慢性盆腔疼痛综合征(CPPS)的有效性和安全性。方法:按照NIH分类标准,采用PPMT法及EPS常规检查,将145例患者分为两组,Ⅲa型组77例,Ⅲb型组68例。两组均口服尼美舒利 100 mg,bid,治疗4周。根据慢性前列腺炎症状评分(CPSI)判断疗效。结果:治疗4周后,两组疼痛症状评分、生活质量评分及总CPSI评分均有明显改善(P<0.05或P<0．01),其中Ⅲa型组EPS中WBC计数评分较治疗前有明显减少(P<0．05)。Ⅲa型组总有效率为84．5％,Ⅲb型组总有效率为83．30%,两组间总有效率差异无统计学竟义(P >0.05)。两组治疗期间均无严重不良事件发生。结论:尼美舒利治疗慢性盆腔疼痛综合征是安全、有效的。

Objective： To investigate the efficacy and safety of nimesulide in the treatment of chronic pelvic pain syndrome （CPPS）. Method： According to the classification worked out by the National Institute Health （NIH）, 145 cases of chronic prostatitis were divided into type Ⅲa group and type Ⅲb group by PPMT （pre- and post-massage test） and EPS （expressed prostate secretion） routine. All the patients were treated with nimesulide 100mg twice a day for 4 weeks. The efficacy was evaluated by the NIH chronic prostatitis symptom index （NIH-CPSI）, Result： After 4 weeks＇ treatment, the pain scores, quality-of-life scores and total CPSI scores were significantly reduced in both groups （P 〈 0.05 or P 〈 0.01）, the mean number of WBC in EPS was significantly decreased in Ⅲa group （P 〈 0.05）. The total effective rates were 84.5% in Ⅲa group and 83.3% in m b group. The total effective rates between the two groups had no significant difference （P 〉 0.05）. No serious side effects occurred. Conclusion： Nimesulide is effective and safe for the treatment of CPPS.